Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases
Granted 23 Feb 2016 · 3 office actions
Current assignee: BAYER PHARMA AKTIENGESELL SCHAFT · originally Bayer Corporation
Law firm: Law firm · Log in to unlock
Attorney: Attorney · Log in to unlock
Inventors: Mark Jean Gnoth, Volker Schulze, Vera Pütter, Marion Hitchcock +11 · Examiner: Deepak Rao · AU 1624 · TC 1600
Life of the application
10 dated eventsAbstract
Compounds of formula (I) which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals. [structure]
Claims as granted
26 claimsLog in to read the claims of this application.
Log in to unlockClassifications
8 codes- A61K31/5383
- A61K31/5377
- A61K45/06
- A61K31/506
- C07D413/14
- C07D498/04
- C07D401/14
- C07D405/14
Claim changes
SoonSee which claims were amended, added or cancelled during examination, with every added and removed word marked.
The published claims of this application are not paired with the granted ones in what we hold.
File wrapper
See the full prosecution history — every USPTO and applicant action on this file, in order.
Log in to unlockDocuments
Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.
Log in to unlockChain of title
No assignments have been recorded for this application yet.